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INTRODUCTION
Despite numerous development in antiepileptic drug
(AED) therapy, epilepsy remains uncontrolled in a signifi-
cant proportion of patients, even with appropriate polyther-
apy at maximal tolerated doses (1). The continued occur-
rence of seizures is a major health problem, and it increases
the risk of death from epilepsy. Although the biologic basis
of medically intractability, or pharmacoresistance, is poorly
understood, it is likely that, just as epilepsy itself is a het-
erogeneous condition with multiple etiologies, the patho-
genesis of ‘‘refractoriness’’ is multifactorial and may include
both genetic and environmental factors (2, 3). 
Ion channel impairment has recently emerged as a poten-
tial factor for AED resistance. Since neuronal excitability is
critically governed by the interaction of voltage- and ligand-
gated ion channels (4), it is not surprising that ion channel
alterations may be pathogenic causes of AED resistance. The
clues come from different sources: 1) most currently avail-
able AEDs exert strong effects on ionic currents (5); 2) in
animal epilepsy models, the density, distribution, molecular
structure, and function of ion channels are altered after seizure
(6); and 3) some specific epilepsy syndromes have been shown
to be associated with distinct ion channel mutations (7). These
clues indicate that the voltage-gated sodium channel is cru-
cially involved in AED resistance.
Gene-to-gene interaction has been thought to be a prima-
ry mechanism underlying the pathogenesis of many multi-
factorial disorders or conditions (8-10). In spite of this, most
candidate gene association studies typically assess the effects
of candidate genes independently of each other. This is par-
tially due to the limitations of parametric-statistical meth-
ods for detecting gene effects that are solely or partially depen-
dent on interactions with other genes (11). For example, logis-
tic regression is less practical for dealing with high-dimen-
sional data, because when high-order gene-to-gene interac-
tions are modeled, there are many contingency-table cells
that contain no observations, which can lead to very large
coefficient estimates and standard errors. One solution to
this problem is to collect very large numbers of samples to
allow for robust estimation of interaction effects; however,
the magnitudes of the samples that are often required incur
prohibited expense. To address this issue, a new statistical
and computational method, the multifactor-dimensionality
reduction (MDR) method, has been developed for detecting
and characterizing high-order gene-to-gene interactions in
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Gene-to-Gene Interaction between Sodium Channel-Related Genes
in Determining the Risk of Antiepileptic Drug Resistance
The pathogenesis of antiepileptic drug (AED) resistance is multifactorial. However,
most candidate gene association studies typically assess the effects of candidate
genes independently of each other, which is partly because of the limitations of the
parametric-statistical methods for detecting the gene-to-gene interactions. A total
of 200 patients with drug-resistant epilepsy and 200 patients with drug-responsive
epilepsy were genotyped for 3 representative the single nucleotide polymorphisms
(SNPs) of the voltage-gated sodium channel genes (SCN1A, SCN1B, and SCN2A)
by polymerase chain reaction and direct sequencing analysis. Besides the typical
parametric statistical method, a new statistical method (multifactor dimensionality
reduction [MDR]) was used to determine whether gene-to-gene interactions increase
the risk of AED resistance. None of the individual genotypes or alleles tested in the
present study showed a significant association with AED resistance, regardless of
their theoretical functional value. With the MDR method, of three possible 2-locus
genotype combinations, the combination of SCN2A-PM with SCN1B-PM was the
best model for predicting susceptibility to AED resistance, with a p value of 0.0547.
MDR, as an analysis paradigm for investigating multi-locus effects in complex dis-
orders, may be a useful statistical method for determining the role of gene-to-gene
interactions in the pathogenesis of AED resistance. 
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case-control studies with relatively small samples (10). 
In the present study, single nucleotide polymorphisms
(SNPs) of three voltage-gated sodium channel genes and their
estimated allele frequencies were identified using a DNA
pool. The independent effects of a representative SNP from
each gene on AED resistance were assessed, and the MDR
method was used to detect possible gene-to-gene interactions
among the voltage-gated sodium channel genes in the patho-
genesis of pharmacoresistance to AEDs. 
MATERIALS AND METHODS
Subjects
Consecutive patients with an established clinical diagno-
sis of epilepsy were recruited from the epilepsy clinics at 2
third-referral hospitals. All study participants were eligible
if they had either drug-resistant (DR group, n=200) or drug-
responsive epilepsy (DS group, n=200) according to the fol-
lowing definitions and criteria. Drug resistance was defined
as the occurrence of at least four unprovoked seizures over the
year before recruitment with trials of more than two appro-
priate AEDs at maximal tolerated doses, which were estab-
lished on the basis of the occurrence of clinical side effects at
supramaximal doses. Patients who had undergone surgical
treatment for drug-resistant epilepsy were classified as hav-
ing drug-resistant epilepsy, regardless of the surgical outcome.
However, patients who were frequently in poor compliance
with AED therapy and those who had reported seizures with
a questionable semiology were excluded from the present
study. In patients treated with single AED, drug responsive-
ness was defined as complete freedom from seizures for at
least one year, up to the date of the last follow-up visit, Demo-
graphic and clinical characteristics by case (drug refractory)-
control (drug responsive) status are described in Table 1. Each
AED listed in Table 1 has been known that the mechanism
of action is closely associated with sodium-channel blocking
(12). The study was approved by the Institutional Review
Board of the hospital, and informed consent was obtained
from all study participants.
DNA pooling
Genomic DNA was extracted from peripheral blood lym-
phocytes using a standard protocol. For the time and cost-
effective screening of SNPs with a relatively high minor allele
frequency (MAF) in the candidate sodium channel-related
genes (SCN1A, SCN1B, and SCN2A), a pool of DNA was
established from each of healthy control, DR or DS groups
using the protocol recommended by the manufacturer (Pico-
Green dsDNA Quantitation Reagent, Molecular Probes, OR,
U.S.A.). In brief, double-stranded DNAs were stained with
an ultrasensitive fluorescent dye (PicoGreen dsDNA Quan-
titation Reagent, Molecular Probes) and the total amount of
fluorescent-stained DNA in each individual was measured
by a fluorometer (PicofluorTM‚ Handheld Fluorometer, Molec-
ular Probes). An equal amount of DNA from 200 subjects
per group was mixed into a pool.
SNP development and the estimation of their relative
allele frequencies
About 1.5 kbp of the 5′ -directed region as well as all cod-
ing regions, including exon-intron boundary sequences of
each candidate gene (SCN1A, SCN1B or SCN2A), were am-
plified by polymerase chain reaction (PCR). A total of 87 ap-
propriate forward and reverse primer sets for each gene (37 for
SCN1A, 11 for SCN1B, and 39 for SCN2A; data not shown in
detail) were prepared based on GenBank sequences (acces-
sion number: NM_006920 for SCN1A, NM_001037 for
SCN1B and NM_006920 for SCN2A). PCR assays were car-
ried out using 1.25 U of AmpliTaq Polymerase Gold (Ap-
plied Biosystems, CA, U.S.A.), 100 ng of pooled DNA, 2.0-
2.5 mM of MgCl2, and 10 μ M of primer. The amplification
conditions were as follows: an initial denaturation cycle at 95℃
for 5 min, followed by 35 amplification cycles (denaturation
at 95℃for 30 sec, annealing at 58℃for SCN1A-PM, 62℃
for SCN1B-PM, and 57℃ for SCN2A-PM for 30 sec, and
extension at 72℃ for 1 min), and a final extension at 72℃
for 7 min. The PCR products were electrophoresed in a 1.2%
*, Fourty-three patients in responsive group needed a second drug
because of various adverse effects from initial therapy.
AED, antiepileptic drug.
Responsive
group
(N=200)
Refractory
group
(N=200)
Gender, man (%) 101 (50.5) 97 (48.5)
Age of seizure onset (yr) 17.35±16.3 12.01±11.27
Seizure classification (%)
Idiopathic, generalized 26 (13.0) 5 (2.5)
Idiopathic, partial 19 (9.5) 0 (0.0)
Symptomatic, generalized 83 (41.5) 131 (65.5)
Symptomatic, partial  47 (23.5) 29 (14.5)
Unclassified 25 (12.5) 35 (17.5)
Brain imaging (%)
Normal 75 (37.5) 58 (29.0)
Focal lesion 50 (25.0) 88 (44.0)
Not available 75 (37.5) 54 (27.0)
Number of used drug (range) 1-2* 2-7
First AED in treatment (%)
Carbamazepine 115 (57.5) 129 (64.5)
Valproate 36 (18.0) 43 (21.5)
Phenytoin 14 (7.0) 15 (7.5)
Oxcarbazepine 13 (6.5) 6 (3.0)
Topiramate 5 (2.5) 5 (2.5)
Zonisamide 2 (1.0) 0 (0.0)
Lamotrigine 1 (0.5) 2 (1.0)
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agarose gel, and the amplified genomic DNA fragments were
extracted from the gel and purified using a QIAquick
� gel
extraction kit (Quiagen, Hilden, Germany) according to the
manufacturer’s instructions. Direct sequencing of both strands
was performed using BigDye terminator kits (PE Biosys-
tems, CA, U.S.A.) and each electropherogram was analyzed
visually using Chromas 2.13 (Technelysium Pty Ltd, Queens-
land, Australia). 
The relative allele frequencies for all SNPs determined in
this study were estimated using the comparative method
proposed by Kwok et al. (Fig. 1). In order to identify indi-
vidual heterozygotes for the representative SNPs, 10 random
individual DNAs consisting of the pooled DNA were geno-
typed using exact same PCR conditions as those used for the
pooled DNA. 
Case-control association study
Based on the estimated allele frequencies of the SNPs and
their theoretical functional value, one SNP per gene was
selected as a representative marker for the case-control study
in which an association of each marker with AED resistance
would be elucidated. The representative markers were as fol-
lows: SCN1A-PM located in exon 16 of SCN1A, SCN1B-
PM located in exon 3 of a splice variant of SCN1B and SC-
N2A-PM located in intervening intronic sequences between
exon 7 and 8 of SCN2A. Both SCN1A-PM and SCN1B-PM
were selected as they are nonsynonymous mutations that may
have functional value. Because there was no detectable SNP
in the exonic sequences of SCN2A in this study, an intronic
SNP (SCN2A-PM) showing the maximum difference of
estimated MAF between DR and DS groups was selected as
a representative marker for SCN2A. However, the substan-
tial value of each SNP still remains to be clear.
A total of 200 patients with drug-resistant epilepsy (DR
Fig. 1. A comparative analysis for estimating relative allele frequen-
cies in a pool of DNA. Allele frequency in pooled DNA={[Refer-
ence Peak Height (Individual)/Reference Peak Height (Pool)]/[Het-
erozygote Peak Height (Individual)/Heterozygote Peak Height
(Pool)]}x 0.5. Black arrows indicate heterozygote peaks and red
arrows indicate reference peaks.
Individual
Pooled
DNA
Fig. 2. The four general steps invol-
ved in using the MDR method for
case-control studies (adapted from
Ritchie et al., 2001). In step 1, a set
of n genetic factors is selected from
the pool of all factors. In step 2, the
n factors and their possible multifac-
tor classes or cells are represented
in n dimensional space. For exam-
ple, for three loci with three geno-
types each, there are 27 three-locus-
genotype combinations. The ratio of
the number of cases is then estimat-
ed within each multifactor class. In
step 3, each multifactor cell in n-di-
mensional space is labeled either
as ‘‘high-risk,’’ if the cases:control
ratio meets or exceeds the given
threshold (e.g., ≥1.0), or as ‘‘low-
risk,’’ if that threshold is not exceed-
ed. This reduces the n-dimensional
model to a one-dimensional model.
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STEP 3: Identify high-
risk multilocus genotypes
Finally, in step 4, the prediction error of each model is estimated by 10-fold cross-validation. Here, the data (i.e., subjects) are randomly
divided into 10 equal parts. Each possible 9/10 of the subjects is used to make predictions regarding the disease status of each possible
1/10 of the subjects excluded. To reduce the possibility of poor prediction error estimates due to the chance division of the data set, the
10-fold cross-validation is repeated 10 times, and the prediction errors are averaged.
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group) and 200 patients with drug-responsive epilepsy (DS
group) were genotyped for 3 representative SNPs by PCR
and direct sequencing analysis. The distribution of each geno-
type of the SNPs between the DR and DS groups were com-
pared statistically by chi-square analysis with Fisher’s exact
test. The relative risk of AED resistance in patients with the
mutant allele was estimated by comparison with the wild-
type allele by logistic regression analysis. Data were analyzed
with SPSS (release 14 OK, Chicago, IL, U.S.A.) and differ-
ences were considered significant for p values of ≤0.05. Con-
formance with the Hardy-Weinberg equilibrium was tested
by comparing the observed and expected genotype frequen-
cies of the controls using the chi-square test.
MDR analysis
A new statistical method, MDR, was introduced to identi-
fy whether gene-to-gene interactions among SCN1A, SCN1B,
and SCN2A increase the risk of AED resistance.
Briefly, most parametric-statistical methods, such as logis-
tic regression analysis, are less practical for dealing with high
dimensional data. However, with MDR, multilocus geno-
types are pooled into high-risk and low-risk groups, effec-
tively reducing the genotype predictors from n dimensions
to one dimension. The new, one-dimensional multilocus-
genotype variable was evaluated for its ability to classify and
predict disease status through cross-validation and permu-
tation testing (Fig. 2). The null hypothesis of no association
was rejected when the p value derived from the permutation
test was ≤0.05. 
RESULTS
SNP developments and estimation of allele frequency in
pooled DNA 
A total of 18 biallelic SNPs in 3 sodium channel-related
genes were identified using a pooled DNA from 200 con-
trol subjects: 10 from SCN1A, 2 from SCN1B and 6 from
SCN2A (data not shown in detail). The SNPs found in exon
16 of SCN1A and in exon 3 in a splice variant of SCN1B
were nonsynonymous mutations that resulted in amino acid
changes from alanine to threonine and leucine to proline,
respectively.
The MAF of each tested SNP estimated in the pool of DNA
from 200 control subjects using a comparative method was
compared with that observed in the individual genotyping
of the pool in Table 2. A biallelic SNP with an MAF of about
0.01 (SCN1A-PM) could be identified with an observation-
al error of 0.005. The maximum amount of observational
error was 0.019, which is consistent with the result of a pre-
vious study (13). 
Association of SNPs in sodium channel-related genes
with AED resistance
None of the individual genotypes tested in the present
study showed a significant association with AED resistance,
MAF, minor allele frequency; △, (Estimated-Observed MAF).
AED, antiepileptic drug; CI, confidence interval. 
Minor allele
Estimated
MAF
Observed
MAF (N=200) △
SCN1A PM-G 0.093 0.085 0.008
SCN1B PM-C 0.297 0.278 0.019
SCN2A PM-T 0.483 0.478 0.005
Table 2. Estimated and observed minor allele frequency 
*, The best combination of attributes for each order model; 
� , p value for
Sign test.
AED, antiepileptic drug. 
Best model*
Training 
accuracy
Testing 
accuracy
CV 
consistency
p
value
�
SCN2A 0.5433 0.4725 5/10 0.8281
SCN2A/SCN1B 0.5692 0.535 10/10 0.0547
SCN2A/SCN1B/ 0.5756 0.5313 10/10 0.1719
SCN1A
Table 5. Gene-to-gene interaction in determining the risk of AED
resistance
Polymorphisms Genotypes
p
value
Responsive
group 
(N=200)
Refractory
group 
(N=200)
SCN1A-PM AA 167 (83.5) 171 (85.5)
GA 32 (16.0) 26 (13.0) 0.434
GG 1 (0.5) 3 (1.5)
SCN1B-PM TT 104 (52.0) 119 (59.5)
CT 81 (40.5) 70 (35.0) 0.297
CC 15 (7.5) 11 (5.5)
SCN2A-PM CC 50 (25.0) 58 (29.0)
CT 109 (54.5) 95 (47.5) 0.375
TT 41 (20.5) 47 (23.5)
Table 3. Genotype distributions of 3 polymorphisms in sodium
channel-related genes 
Polymorphisms
p
value
Genotypes Exp (β )
Odds ratio
(95% CI)
SCN1A-PM AA vs. GA 0.341 0.035-3.314 0.354
AA vs. GG 0.271 0.027-2.760 0.270
AA vs. GG/GA 1.165 0.677-2.005 0.581
SCN1B-PM TT vs. CT 1.56 0.686-3.547 0.288
TT vs. CC 1.178 0.508-2.733 0.702
TT vs. CC/CT 1.356 0.913-2.015 0.131
SCN2A-PM CC vs. CT 1.315 0.797-2.191 0.284
CT vs. TT 1.331 0.834-2.125 0.231
TT vs. TT/CT 1.225 0.787-1.907 0.368
Table 4. The odds ratios of genotypes for AED resistance66 S.-Y. Jang, M.-K. Kim, K.-R. Lee, et al.
regardless of their theoretical functional value (Table 3). The
risk for susceptibility to AED resistance in patients with the
mutant allele in each SNP was not significant when com-
pared with that of the wild-type allele (Table 4). 
Association between gene-to-gene interaction and AED
resistance 
In the absence of any statistically significant independent
primary effect, the association of multi-locus genotype com-
binations with AED resistance was analyzed by MDR (Table
5). Of the three possible 2-locus genotype combinations, the
combination of SCN2A-PM with SCN1B-PM was the best
model for predicting susceptibility to AED resistance with
a p value of 0.0547 (Fig. 3). In the model, the cross-valida-
tion consistency was 10/10, meaning that this model was
selected as the best model in all 10 cross-validation tests.
The three-locus genotype combination did not reach statis-
tical significance in predicting susceptibility to AED resis-
tance (p=0.1719). Both SCN2A-PM and SCN1B-PM were
synergistic in predicting susceptibility to AED resistance.
However, every combination of the interaction that includ-
ed SCN1A-PM provided redundant information (Fig. 4).  
DISCUSSION
Mechanisms of AED resistance are related to drug meta-
bolism, drug transporters, drug targets, and ion channels (14-
16). Over the past decade, much attention has been focused
on both cytochrome P450 enzymes, which have the poten-
tial to affect AED metabolism, and membrane efflux trans-
porters, such as ATP-binding cassette subfamily B member
1 (ABCB1) (15, 16). One of the most significant advances in
our understanding of the role of genetic factors in the patho-
genesis of AED resistance came from Siddiqui et al., who
reported an association between multidrug resistance in epi-
lepsy and a polymorphism in the drug transporter gene ABCB1,
which appears to confer a susceptibility to AED refractori-
ness (17). However, recently published studies provide appar-
ently conflicting evidence on the association between the
ABCB1 gene and AED resistance (16, 18). 
Voltage-gated sodium channels are essential for the initi-
ation and propagation of action potentials in neurons, which
is the basic requirement for the neuronal excitability under-
lying epileptogenesis, and they are the targets of most of the
currently available AEDs (16). In addition, with the remark-
able advances in molecular genetics, it has been known that
at least 3 voltage-gated sodium channel genes (SCN1A, SC-
N1B or SCN2A gene) are directly associated with a number
of epilepsy syndromes (19, 20). In this context, impairments
in the functions of voltage-gated sodium channels may be
potential mechanisms of the pathogenesis underlying the
general resistance to AED therapy. However, to our knowl-
edge, there has been no report on this topic thus far. 
In the present study, representatives SNPs from the SC-
N1A, SCN1B or SCN2A genes were analyzed to determine
whether each SNP was independently with AED resistance.
Even though two of the SNPs tested were nonsynonymous
mutations that resulted in amino acid changes, no significant
association was found between each SNP and AED resistance
(Table 3, 4). However, it is not clear whether these results
truly mean that the voltage-dependent sodium channel genes
do not contribute to the pathogenesis of AED resistance under
any circumstance. An alternative explanation for the results
is either that the independent contribution of each gene to
AED resistance may have been too weak to be detected with
Fig. 3. Best multi-locus model for susceptibility to AED resistance.
High-risk genotypes as revealed by MDR are in dark shading
and the low-risk genotypes are in light shading. The numbers of
individuals with refractory epilepsy are represented within each
cell as the left-hand bar of the histogram and the number of indi-
viduals with responsive epilepsy are in the right-hand bar.
Fig. 4. The dendrogram demonstrates the nature of the interac-
tions between SNPs. The colors used in the dendrogram com-
prise a spectrum of colors representing a continuum from syner-
gy to redundancy. 
S
C
N
1
B
 
P
M
 
C
/
T
CC
CT
TT
CC
SCN2A PM C/T
CT TT
44 4 9
3 2
19 17
29
49
22
15
35
29
62
51
22 24
SCN1A-PM A/G
SCN2A-PM C/T
Synergy
Redundancy
SCN1B-PM C/TGene-to-gene Interaction in Antiepileptic Drug Resistance 67
classic parametric statistical methods in the setting of a small
number of samples or that the SNP selected from each gene
may not have been a real representative of the gene in terms
of its function. As a first step to answering these questions,
the MDR method was introduced in the present study to
determine whether one of the weak contributions was impli-
cated in AED resistance. It is our working hypothesis that
for some genes these gene-to-gene interactions may be more
important than the independent effects of the single genes.
With the MDR method used in the present study (Table 5),
the best single locus model selected was a SCN2A-PM mark-
er with a p value of 0.8281, suggesting that the power of the
marker in predicting susceptibility to AED resistance is very
weak. This result is consistent with that of the parametric
statistical analysis. The best multi-locus MDR model select-
ed SCN2A-PM and SCN1B-PM with a p value of 0.0547
in two-gene interaction settings. Although, as in the single
locus MDR models, the interaction between SCN2A-PM
and SCN1B-PM did not agree with the working hypothesis
at a level of statistical significance in this study, it is clear
that gene-to-gene interaction is more important than any
independent effect of single genes in predicting susceptibil-
ity to AED resistance. The three-gene-interaction model did
not increase the power of predicting AED resistance when
compared with the two-gene-interaction model. It also con-
tributes to the increasing amount of evidence that gene-to-
gene interactions are potential causes of common multifac-
torial disorders, such as AED resistance, by demonstrating
that some genes are synergistic in their ability to produce
refractoriness to AED therapy while others are redundant.
In our cases, SCN2A-PM and SCN1B-PM were synergistic
in increasing the predictive power, while SCN1A-PM acted
as a redundant factor. 
It has been known that pooling an equal amount of DNA
from individual samples and measuring the relative abun-
dance of alleles in the pool is an efficient strategy for estimat-
ing allele frequencies in many samples because it drastically
reduces the cost of the analysis and the amount of DNA con-
sumed when compared to genotyping individuals and count-
ing alleles (13, 21-23). Obviously, the method used to geno-
type SNPs in pooled DNA must provide an accurate esti-
mation of allele frequencies and must be time and cost effec-
tive. In this study, the method proposed by Kwok et al. (13)
was used to genotype SNPs and estimate their allele frequen-
cies in a pool of DNA. The accuracy of the method in esti-
mating allele frequency was verified, along with its time and
cost effectiveness (Table 2). This provides proof that the selec-
tion of the representative SNPs based on the results from
the analysis using pooled DNA was appropriate for associa-
tion studies.
A limitation of the present study was that the number and
characteristics of the variables (SNPs tested) were not suffi-
cient to support an intrinsic value of the MDR method in
dissecting the gene-to-gene interactions that underlie AED
resistance. In reality, there is no evidence that AED resistance
is determined by the neuronal excitability associated with
sodium channel genes alone (14). Another limitation of this
study is that the SNPs tested in this study were selected by
their theoretical functional value and not by their intrinsic
value. This means that, in certain circumstances, a SNP with
a stronger effect than the SNP used can be obtained in the
corresponding gene. Therefore, further studies that include
various genes with various mechanisms underlying AED resis-
tance and that cover all SNPs developed in a gene are needed.
Taken together, the results of this study show that the
recent controversies in the previous studies concerning AED
resistance (16, 18) might have been partly caused by the inves-
tigators’ blind belief in a single gene effect on the complex
phenotype as well as ethnic differences in the distribution of
the SNPs tested. MDR, as an analysis paradigm for investi-
gating multi-locus effects in complex disorders, may be a use-
ful statistical method for determining the role of gene-to-
gene interactions in the pathogenesis of AED resistance. To
our knowledge, this is the first report of a possibility that
gene-to-gene interactions associated with AED resistance
may be more important than the independent effects of the
single genes.
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